PETRA GUILMAIN: Open Payments
NPI 1831723881 · HAMBURG, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,958 in 267 payments from 20 companies in 2025. Trend: 2023 $3,481 · 2024 $4,237 · 2025 $5,958
Food & beverage: $4,888Travel & lodging: $1,070
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 61 | $1,221 |
| Neuronetics, Inc. | 3 | $1,194 |
| Otsuka America Pharmaceutical, Inc. | 29 | $592 |
| Neurocrine BioSciences, Inc. | 17 | $434 |
| Teva Pharmaceuticals USA, Inc. | 26 | $357 |
| Lundbeck LLC | 27 | $356 |
| Janssen Pharmaceuticals, Inc | 12 | $296 |
| Axsome Therapeutics, Inc. | 22 | $262 |
| Vanda Pharmaceuticals Inc. | 7 | $246 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $246 |
Products named: VRAYLAR, NEUROSTAR TMS THERAPY SYSTEM, REXULTI, INGREZZA, SPRAVATO, Auvelity, FANAPT, CAPLYTA.
Industry payments across NY — which companies pay providers there.
